Figure 4.
TRAIL sensitivity of HPMC is linked to low expression of MHC class I and high expression of DR5 death receptor
(A and B) Expression of MHC class I genes (HLA-A, HLA-B, HLA-C) (A) and TRAIL receptor genes (TNFRSF10A, TNFRSF10B, TNFRSF10C, TNFRSF10D). (B) In HPMC (from omentum) compared to tumor cells and TAT (from ascites) from HGSC patients according to RNA-Seq datasets as described previously.24 TPM values are depicted from n = 5 HPMC, n = 34 tumor cells and n = 6 TAT of different patients.
(C) The expression of TRAIL receptors (DR4, DR5, DcR1, DcR2) on ex vivo tumor cells (n = 12 patients) and cultured HPMC from HGSC patients (n = 8 patients) and control HPMC originated from patients with benign gynecological diseases (Ctrl HPMC, n = 6 patients) was further validated on protein-level via flow cytometry. The geometric MFI minus the isotype control is depicted.
(D) Overlay of representative histograms showing the TRAIL receptor expression (DR4, DR5, DcR1, DcR2) in comparison to the isotype controls for HPMC and tumor cells from HGSC patients are presented.
The mean is shown by horizontal bars and vertical error bars represent the standard deviation. ∗ FDR < 0.05; ∗∗ FDR < 0.01; ∗∗∗ FDR < 0.001; ∗∗∗∗ FDR < 0.0001 determined by unpaired t test and Benjamini-Hochberg adjustment (ns: not significant).